| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cef4f341fe4f2caf061611a818576e40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D275-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 |
| filingDate |
2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afcf9cbb0e8882d5aa3cc5e308c8a36a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02b0c936e35f3a2b576895d65d8c4906
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b416ff9ac5662635c75107ed8a75e136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98f3ea7f05596b620d9fb8ccc9c90b71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e9f3b4a1114c0defe75b6678cb3a0e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_596394a6e3629b40a40e7a63ee1f4ba1 |
| publicationDate |
2017-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112015020152-A2 |
| titleOfInvention |
2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1h) -one salts derivatives having both beta2 adrenergic receptor agonist activity and m3 muscarinic receptor antagonist activity |
| abstract |
Patent Summary: "Derived from 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2 (1h) -one salts having both beta2 adrenergic receptor agonist activity and m3 muscarinic receptor antagonist activity". The present invention relates to crystalline addition salts of (i) 8-hydroxyquinolin-2 (1h) -one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvate thereof. |
| priorityDate |
2013-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |